High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer

Cancer statistics, 2009

Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709

Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain

Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634

Cell Survival Responses to Environmental Stresses Via the Keap1-Nrf2-ARE Pathway

Kensler, T. W., Wakabayashi, N., & Biswal, S. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141046 · Cited by 3,630

Cancer chemoprevention with dietary phytochemicals

Surh, Y.-J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1189 · Cited by 2,955

Two pathogenetic types of endometrial carcinoma

Bokhman, J. V. (1983) · Gynecologic Oncology · doi:10.1016/0090-8258(83)90111-7 · Cited by 2,508

Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2

Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224

Keap1 Is a Redox-Regulated Substrate Adaptor Protein for a Cul3-Dependent Ubiquitin Ligase Complex

Zhang, D. D., Lo, S., Cross, J. V., Templeton, D. J., & Hannink, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10941-10953.2004 · Cited by 1,284

Mechanistic Studies of the Nrf2-Keap1 Signaling Pathway

Zhang, D. D. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600971974 · Cited by 1,105

Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice

Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102

Dysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer

Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060

Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke–induced emphysema in mice

Rangasamy, T., Cho, C. Y., Thimmulappa, R. K., Zhen, L., Srisuma, S., Kensler, T. W., Yamamoto, M. P., Petrache, I., Tuder, R. M., & Biswal, S. S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21146 · Cited by 993

NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer

Hayes, J. D., & McMahon, M. J. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.12.008 · Cited by 870

Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2

Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839

Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer

Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735

Role of NRF2 in Protection Against Hyperoxic Lung Injury in Mice

Cho, H., Jedlicka, A., Reddy, S. P., Kensler, T. W., Yamamoto, M. P., Zhang, L.-Y., & Kleeberger, S. R. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.26.2.4501 · Cited by 660

Dual roles of Nrf2 in cancer

LAU, A., VILLENEUVE, N., Sun, Z., Wong, P. K., & Zhang, D. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.003 · Cited by 653

Direct Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response

Chen, W., Sun, Z., Wang, X.-J., Jiang, T., Huang, Z., Fang, D., & Zhang, D. D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.029 · Cited by 638

Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice

Rangasamy, T., Guo, J., Mitzner, W. A., Roman, J., Singh, A., Fryer, A. D., Yamamoto, M., Kensler, T. W., Tuder, R. M., Georas, S. N., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050538 · Cited by 580

Molecular and Pathologic Aspects of Endometrial Carcinogenesis

Hecht, J. L., & Mutter, G. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7173 · Cited by 536

Theories of Endometrial Carcinogenesis: A Multidisciplinary Approach

Sherman, M. E. (2000) · Modern Pathology · doi:10.1038/modpathol.3880051 · Cited by 511

The Protective Role of Nrf2 in Streptozotocin-Induced Diabetic Nephropathy

Jiang, T., Huang, Z., Lin, Y., Zhang, Z., Fang, D., & Zhang, D. D. (2010) · Diabetes · doi:10.2337/db09-1342 · Cited by 440

RNAi -Mediated Silencing of Nuclear Factor Erythroid-2–Related Factor 2 Gene Expression in Non–Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy

Singh, A., Boldin‐Adamsky, S., Thimmulappa, R. K., Rath, S. K., Ashush, H., Coulter, J. B., Blackford, A. L., Goodman, S. N., Bunz, F., Watson, W. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1401 · Cited by 371

Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin

Kim, Y. R., Oh, J. E., Kim, M. S., Kang, M. R., Park, S. W., Han, J. Y., Eom, H., Yoo, N. J., & Lee, S. H. (2009) · The Journal of Pathology · doi:10.1002/path.2653 · Cited by 357

Effects of Glucosinolate-Rich Broccoli Sprouts on Urinary Levels of Aflatoxin-DNA Adducts and Phenanthrene Tetraols in a Randomized Clinical Trial in He Zuo Township, Qidong, People's Republic of China

Kensler, T. W., Chen, J., Egner, P. A., Fahey, J. W., Jacobson, L. P., Stephenson, K. K., Ye, L., Coady, J. L., Wang, J.-B., Wu, Y., et al. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0368 · Cited by 317

Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1–NRF2 pathway, and not the BACH1–NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds

MacLeod, A. K., McMahon, M. J., Plummer, S. M., Higgins, L. G., Penning, T. M., Igarashi, K., & Hayes, J. D. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp176 · Cited by 305

Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes

Yates, M. S., Tauchi, M., Katsuoka, F., Flanders, K. C., Liby, K. T., Honda, T., Gribble, G. W., Johnson, D. A., Johnson, J. A., Burton, N. C., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0516 · Cited by 292

Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-Imidazolide

Shin, S., Wakabayashi, J., Yates, M. S., Wakabayashi, N., Dolan, P. M., Aja, S. M., Liby, K. T., Sporn, M. B., Yamamoto, M. P., & Kensler, T. W. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.08.022 · Cited by 275

A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity

Nioi, P., & Nguyen, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.051 · Cited by 212

Nrf2 as a target for cancer chemoprevention

Yu, X. Y., & Kensler, T. W. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2005.04.017 · Cited by 199

In vivo modulation of the Parkinsonian phenotype by Nrf2

Burton, N. C., Kensler, T. W., & Guilarte, T. R. (2006) · NeuroToxicology · doi:10.1016/j.neuro.2006.07.019 · Cited by 187

Transcription factor Nrf2 mediates an adaptive response to sulforaphane that protects fibroblasts in vitro against the cytotoxic effects of electrophiles, peroxides and redox-cycling agents

Higgins, L. G., Kelleher, M., Eggleston, I. M., Itoh, K., Yamamoto, M. P., & Hayes, J. D. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.03.005 · Cited by 178

Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: Implication to cancer cell resistance

Cho, J., Manandhar, S., Lee, H., Park, H.-M., & Kwak, M. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.10.022 · Cited by 167

Resistance to chemotherapy and hormone therapy in endometrial cancer

Chaudhry, P., & Asselin, É. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0266 · Cited by 137

Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway

Shim, G.-S., Manandhar, S., Shin, D., Kim, T., & Kwak, M. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.006 · Cited by 131

Nrf2 protects against As(III)-induced damage in mouse liver and bladder

Jiang, T., Huang, Z., Chan, J. Y., & Zhang, D. D. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.06.010 · Cited by 92

Prognostic factors in endometrial carcinoma

Uharček, P. (2008) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2008.00796.x · Cited by 89

Dietary Cancer Chemopreventive Agents – Targeting Inflammation and Nrf2 Signaling Pathway

Khor, T. O., Yu, S., & Kong, A. T. (2008) · Planta Medica · doi:10.1055/s-0028-1088303 · Cited by 64

Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.

Nordström, B., Strang, P. M., Lindgren, A., Bergström, R., & Tribukait, B. (1996) · PubMed · Cited by 36

Clinical aspects of uterine papillary serous carcinoma

Hamilton, C. A., Kapp, D. S., & Chan, J. K. (2008) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3282f2b10d · Cited by 28

Ultrastructural characterization of two new human endometrial carcinoma cell lines and normal human endometrial epithelial cells cultured on extracellular matrix

Boyd, J. A., Rinehart, C. A., Walton, L. A., Siegal, G. P., & Kaufman, D. G. (1990) · In Vitro Cellular & Developmental Biology - Plant · doi:10.1007/bf02624426 · Cited by 25

Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy

Forman, H. J., & Zhang, H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00233-1 · Cited by 2,900

Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution

Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478

Ferroptosis: Mechanisms and links with diseases

Yan, H.-F., Zou, T., Tuo, Q.-Z., Xu, S., Li, H., Belaidi, A. A., & Lei, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00428-9 · Cited by 1,471

The emerging role of the Nrf2–Keap1 signaling pathway in cancerPreprint

Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,328

Role of Glutathione in Cancer Progression and Chemoresistance

Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/972913 · Cited by 1,208

Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease

Ngo, V., & Duennwald, M. L. (2022) · Antioxidants · doi:10.3390/antiox11122345 · Cited by 1,130

Antioxidant responses and cellular adjustments to oxidative stress

Espinosa‐Díez, C., Miguel, V., Mennerich, D., Kietzmann, T., Sánchez-Pérez, P., Cadenas, S., & Lamas, S. (2015) · Redox Biology · doi:10.1016/j.redox.2015.07.008 · Cited by 1,121

NRF2 and cancer: the good, the bad and the importance of context

Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067

The cytoprotective role of the Keap1–Nrf2 pathway

Baird, L., & Dinkova‐Kostova, A. T. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0674-5 · Cited by 1,048

Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease

Tebay, L. E., Robertson, H., Durant, S. T., Vitale, S. R., Penning, T. M., Dinkova-Kostova, A. T., & Hayes, J. D. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.021 · Cited by 837

Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism

Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673

Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity

Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., & Hayes, J. D. (2013) · Oncogene · doi:10.1038/onc.2012.388 · Cited by 657

Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors

Singh, A., Venkannagari, S., Oh, K. H., Zhang, Y., Rohde, J. M., Liu, L., Nimmagadda, S., Sudini, K. R., Brimacombe, K. R., Gajghate, S., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00651 · Cited by 626

The complexity of the Nrf2 pathway: beyond the antioxidant response

Huang, Y. S., Li, W., Su, Z., & Kong, A. T. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.08.001 · Cited by 459

Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved?

Görlach, A., Dimova, E. Y., Petry, A., Martı́nez-Ruiz, A., Hernansanz‐Agustín, P., Rolo, A. P., Palmeira, C. M., & Kietzmann, T. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.016 · Cited by 363

Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis

Singh, A., Happel, C., Manna, S. K., Acquaah-Mensah, G., Carrerero, J., Kumar, S., Nasipuri, P., Krausz, K. W., Wakabayashi, N., Dewi, R., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66353 · Cited by 333

Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity

Arlt, A., Sebens, S., Krebs, S., Geismann, C., Großmann, M., Kruse, M.-L., Schreiber, S., & Schäfer, H. (2012) · Oncogene · doi:10.1038/onc.2012.493 · Cited by 338

Reactive oxygen species and fibrosis: further evidence of a significant liaison

Richter, K., & Kietzmann, T. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2445-3 · Cited by 322

Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2

Tao, S., Wang, S., Moghaddam, S. J., Ooi, A., Chapman, E., Wong, P. K., & Zhang, D. D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1439 · Cited by 291

The Nrf2/HO‐1 Axis in Cancer Cell Growth and Chemoresistance

Furfaro, A. L., Traverso, N., Domenicotti, C., Piras, S., Moretta, L., Marinari, U. M., Pronzato, M. A., & Nitti, M. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1958174 · Cited by 295

LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS -Mutant Lung Adenocarcinoma

Galan-Cobo, A., Sitthideatphaiboon, P., Qu, X., Poteete, A., Pisegna, M. A., Tong, P., Chen, P.-H., Boroughs, L. K., Rodriguez, M. L. M., Zhang, W., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3527 · Cited by 292

The Roles of ROS in Cancer Heterogeneity and Therapy

Júnior, P. L. D. S., Câmara, D. A. D., Porcacchia, A. S., Fonseca, P. M. M., Jorge, S. D., Araldi, R. P., & Ferreira, A. K. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2467940 · Cited by 295

NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis

Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6095 · Cited by 289

Emerging avenues linking inflammation and cancer

Kundu, J. K., & Surh, Y. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.02.035 · Cited by 272

Antioxidants: Positive or Negative Actors?

Salehi, B., Martorell, M., Arbiser, J. L., Sureda, A., Martins, N. A., Maurya, P. K., Sharifi‐Rad, M., Kumar, P., & Sharifi‐Rad, J. (2018) · Biomolecules · doi:10.3390/biom8040124 · Cited by 266

Thirty years of NRF2: advances and therapeutic challenges.

Zhang, D. D. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01145-0 · Cited by 282

Redox-fibrosis: Impact of TGFβ1 on ROS generators, mediators and functional consequences

Richter, K., Konzack, A., Pihlajaniemi, T. A., Heljäsvaara, R., & Kietzmann, T. (2015) · Redox Biology · doi:10.1016/j.redox.2015.08.015 · Cited by 244

Arsenic Inhibits Autophagic Flux, Activating the Nrf2-Keap1 Pathway in a p62-Dependent Manner

Lau, A., Zheng, Y., Tao, S., Wang, H., Whitman, S. A., White, E., & Zhang, D. D. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01748-12 · Cited by 229

Nrf2: control of sensitivity to carcinogens

Slocum, S. L., & Kensler, T. W. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0675-4 · Cited by 219

NRF2 activation promotes the recurrence of dormant tumour cells through regulation of redox and nucleotide metabolism

Fox, D. B., Garcia, N. M. G., McKinney, B. J., Lupo, R., Noteware, L. C., Newcomb, R., Liu, J., Locasale, J. W., Hirschey, M. D., & Alvarez, J. V. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0191-z · Cited by 214

Oncogenic functions of the transcription factor Nrf2

Gañán‐Gómez, I., Wei, Y., Yang, H., Boyano-Adánez, M. C., & Garcia‐Manero, G. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.041 · Cited by 200

Antioxidants and HNE in redox homeostasis

Łuczaj, W., Gęgotek, A., & Skrzydlewska, E. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.11.033 · Cited by 201

Methylation of the KEAP1 gene promoter region in human colorectal cancer

Hanada, N., Takahata, T., Zhou, Q., Ye, X., Sun, R., Itoh, J., Ishiguro, A., Kijima, H., Mimura, J., Itoh, K., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-66 · Cited by 189

iASPP Is an Antioxidative Factor and Drives Cancer Growth and Drug Resistance by Competing with Nrf2 for Keap1 Binding

Ge, W., Zhao, K., Wang, X., Li, H., Yu, M., He, M., Xue, X., Zhu, Y., Zhang, C. L., Cheng, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.008 · Cited by 188

The Keap1–Nrf2 system as an in vivo sensor for electrophiles

Uruno, A., & Motohashi, H. (2011) · Nitric Oxide · doi:10.1016/j.niox.2011.02.007 · Cited by 187

NRF2: KEAPing Tumors Protected

Pillai, R., Hayashi, M., Zavitsanou, A.-M., & Papagiannakopoulos, T. Y. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0922 · Cited by 192

NRF2 Activation in Cancer: From DNA to Protein

Cloer, E. W., Goldfarb, D., Schrank, T. P., Weissman, B. E., & Major, M. B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2723 · Cited by 182

Potential Applications of NRF2 Inhibitors in Cancer Therapy

Panieri, E., & Saso, L. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8592348 · Cited by 189

The Nrf2-Keap1-ARE Signaling Pathway: The Regulation and Dual Function of Nrf2 in Cancer

Zhang, D. D. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3301 · Cited by 177

The Keap1–Nrf2 Cell Defense Pathway – A Promising Therapeutic Target?

Copple, I. M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-398339-8.00002-1 · Cited by 174

Molecular mechanisms of Nrf2 regulation and how these influence chemical modulation for disease intervention

Harder, B. G., Jiang, T., Wu, T., Tao, S., de la Vega, M. R., Tian, W., Chapman, E., & Zhang, D. D. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150020 · Cited by 171

Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway

Su, X., Jiang, X. M., Meng, L., Dong, X., Shen, Y., & Xin, Y. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/5438179 · Cited by 172

Dual roles of NRF2 in tumor prevention and progression: Possible implications in cancer treatment

Moon, E. J., & Giaccia, A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.009 · Cited by 160

Dimethyl fumarate, a two‐edged drug: Current status and future directions

Saidu, N. E. B., Kavian, N., Leroy, K., Jacob, C., Nicco, C., Batteux, F., & Alexandre, J. (2019) · Medicinal Research Reviews · doi:10.1002/med.21567 · Cited by 164

An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy

Zhu, J., Wang, H., Chen, F., Fu, J., Xu, Y., Hou, Y., Kou, H. H., Zhai, C., Nelson, M. B., Zhang, Q., et al. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.09.010 · Cited by 162

Role of the Keap1–Nrf2 Pathway in Cancer

Leinonen, H. M., Kansanen, E., Pölönen, P., Heinäniemi, M., & Levonen, A. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-420117-0.00008-6 · Cited by 158

Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance

Mirzaei, S., Mohammadi, A. T., Gholami, M. H., Hashemi, F., Zarrabi, A., Zabolian, A., Hushmandi, K., Makvandi, P., Samec, M., Líšková, A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105575 · Cited by 153

Targeting Nrf2 Signaling to Combat Chemoresistance

No, J. H., Kim, Y.-B., & Song, Y. S. (2014) · Journal of Cancer Prevention · doi:10.15430/jcp.2014.19.2.111 · Cited by 144

Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism

Yu, D., Liu, Y., Zhou, Y., Ruiz‐Rodado, V., Larion, M., Xu, G., & Yang, C. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913633117 · Cited by 142

Arsenic‐Mediated Activation of the Nrf2‐Keap1 Antioxidant Pathway

Lau, A., Whitman, S. A., Jaramillo, M. C., & Zhang, D. D. (2012) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21463 · Cited by 139

Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination

Hast, B. E., Cloer, E. W., Goldfarb, D., Li, H., Siesser, P. F., Yan, F., Walter, V., Zheng, N., Hayes, D. N., & Major, M. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1655 · Cited by 138

The PTEN/NRF2 Axis Promotes Human Carcinogenesis

Rojo, A. I., Rada, P., Mendiola, M., Ortega-Molina, A., Wojdyła, K., Rogowska-Wrzesińska, A., Hardisson, D., Serrano, M., & Cuadrado, A. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.5843 · Cited by 135

Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance

Ryoo, I.-G., Lee, S.-H., & Kwak, M.-K. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2428153 · Cited by 135

Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers

Li, L., Wu, Q., Lu, F., Lei, J., Zhou, Y., Liu, Y., Zhu, N., You, Y., Ning, Z., She, T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1184079 · Cited by 132

MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil

Shi, L., Wu, L. J., Chen, Z., Yang, J., Chen, X., Yu, F., Zheng, F., & Lin, X. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000374036 · Cited by 126

The Tumor Microenvironment: Characterization, Redox Considerations, and Novel Approaches for Reactive Oxygen Species-Targeted Gene Therapy

Policastro, L. L., Ibañez, I. L., Notcovich, C., Duran, H. A., & Podhajcer, O. L. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4367 · Cited by 120

USP15 Negatively Regulates Nrf2 through Deubiquitination of Keap1

Villeneuve, N. F., Tian, W., Wu, T., Sun, Z., Lau, A., Chapman, E., Fang, D., & Zhang, D. D. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.04.022 · Cited by 120

Metabolic features of cancer cells

Wang, Y., Xia, Y., & Lu, Z. (2018) · 癌症：英文版 · doi:10.1186/s40880-018-0335-7 · Cited by 121

RKIP: Much more than Raf Kinase inhibitory protein

Al‐Mulla, F., Bitar, M. S., Taqi, Z., & Yeung, K. C. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24335 · Cited by 117

DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer

Zhang, Q., Zhang, Z.-Y., Du, H., Li, S., Tu, R., Jia, Y., Zheng, Z., Song, X., Du, R., & Zhang, X. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0303-z · Cited by 117

A Proposed Model for Endometrial Serous Carcinogenesis

Zheng, W., Li, X., Fadare, O., & Kong, B. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318202772e · Cited by 115

The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders

Hybertson, B. M., Gao, B., & Doan, A. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s35078 · Cited by 113

NRF2 and p53: Januses in cancer?

Rotblat, B., Melino, G., & Knight, R. A. (2012) · Oncotarget · doi:10.18632/oncotarget.754 · Cited by 114

Regulation ofKEAP1expression by promoter methylation in malignant gliomas and association with patient’s outcome

Muscarella, L. A., Barbano, R., D’Angelo, V., Copetti, M., Coco, M., Balsamo, T., la Torre, A., Notarangelo, A., Troiano, M., Parisi, S., et al. (2011) · Epigenetics · doi:10.4161/epi.6.3.14408 · Cited by 108

Unraveling the molecular genetics of head and neck cancer through genome-wide approaches

Riaz, N., Morris, L. G. T., Lee, W., & Chan, T. A.-T. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.07.002 · Cited by 111

The secretome of colon cancer stem cells contains drug-metabolizing enzymes

Emmink, B. L., Verheem, A., van Houdt, W. J., Steller, E. J. A., Govaert, K. M., Pham, T. V., Piersma, S. R., Rinkes, I. H. M. B., Jiménez, C. R., & Kranenburg, O. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.06.027 · Cited by 108

Redox Imbalance in the Development of Colorectal Cancer

Liu, H., Liu, X., Zhang, C., Zhu, H., Xu, Q., Bu, Y., & Lei, Y. (2017) · Journal of Cancer · doi:10.7150/jca.18735 · Cited by 109

Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition

Hanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102

Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma.

Bao, L.-J., Jaramillo, M. C., Zhang, Z.-B., Zheng, Y.-X., Yao, M., Zhang, D. D., & Yi, X.-F. (2014) · Europe PMC (PubMed Central) · Cited by 104

ABCF2 , an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells

Bao, L., Wu, J., Dodson, M. B., de la Vega, E. M. R., Ning, Y., Zhang, Z., Yao, M., Zhang, D. D., Xu, C., & Yi, X. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22615 · Cited by 101

Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma

Weniger, M. A., Rizzatti, E. G., Pérez‐Galán, P., Liu, D., Wang, Q., Munson, P. J., Raghavachari, N., White, T., Tweito, M. M., Dunleavy, K. M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3367 · Cited by 101

The protein kinase activity of fructokinase A specifies the antioxidant responses of tumor cells by phosphorylating p62

Xu, D., Li, X., Shao, F., Lv, G., Lv, H., Lee, J.-H., Qian, X., Zheng, W., Xia, Y., Du, L., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4570 · Cited by 103

Dysregulation of NRF2 in Cancer: from Molecular Mechanisms to Therapeutic Opportunities

Jung, B.-J., Yoo, H.-S., Shin, S., Park, Y., & Jeon, S. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.195 · Cited by 104

FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1‐Nrf2 signaling

Guan, L., Zhang, L., Gong, Z., Hou, X., Xu, Y., Feng, X., Wang, H., & You, H. (2016) · Hepatology · doi:10.1002/hep.28496 · Cited by 95

Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism

Smolková, K., Mikó, E., Kovàcs, T., Leguina‐Ruzzi, A., Sipos, A., & Bai, P. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8024 · Cited by 101

Ubiquitin networks in cancer

Kirkin, V., & Đikić, I. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.004 · Cited by 95

AberrantKeap1methylation in breast cancer and association with clinicopathological features

Barbano, R., Muscarella, L. A., Pasculli, B., Valori, V. M., Fontana, A., Coco, M., la Torre, A., Balsamo, T., Poeta, M. L., Marangi, G. F., et al. (2012) · Epigenetics · doi:10.4161/epi.23319 · Cited by 92

Aldo–Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers

Matsunaga, T., Wada, Y., Endo, S., Soda, M., El-Kabbani, O. A. L., & Hara, A. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00005 · Cited by 91

Cytoprotection “gone astray’’: Nrf2 and its role in cancer

Schäfer, H., Geismann, C., Arlt, A., & Sebens, S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s36624 · Cited by 91

Targeting NRF2 to treat cancer

Sivinski, J., Zhang, D. D., & Chapman, E. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.003 · Cited by 94

The role of Nrf2 transcription factor in viral infection

Ramezani, A., Parsanahad, M., & Faghihloo, E. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26897 · Cited by 92

Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer

Ma, X., Zhang, J., Liu, S., Huang, Y., Chen, B., & Wang, D. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1722-9 · Cited by 88

The Antioxidant Paradox: What are Antioxidants and How Should They Be Used in a Therapeutic Context for Cancer

Bonner, M. Y., & Arbiser, J. L. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.86 · Cited by 81

Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer

Jeddi, F., Soozangar, N., Sadeghi, M. R., Somi, M. H., Shirmohamadi, M., Eftekhar-Sadat, A.-T., & Samadi, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.129 · Cited by 75

Isothiocyanates protect against oxidized LDL-induced endothelial dysfunction by upregulating Nrf2-dependent antioxidation and suppressing NFκB activation

Huang, C., Lin, A., Liu, C., Tsai, C.-W., Chang, I.-S., Chen, H., & Lii, C. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300063 · Cited by 81

Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers

Tossetta, G., & Marzioni, D. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175503 · Cited by 81

Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism

Bai, M., Yang, L., Liao, H., Liang, X., Xie, B., Xiong, J., Tao, X., Chen, X., Cheng, Y., Chen, X., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0360-7 · Cited by 80

MicroRNA-421 confers paclitaxel resistance by binding to the KEAP1 3′UTR and predicts poor survival in non-small cell lung cancer

Duan, F., Wang, M., Cao, Y., Li, D., Li, R.-Z., Fan, X., Khan, I., Lai, H., Zhang, Y., Hsiao, W. L. W., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2031-1 · Cited by 78

Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer

Kim, E. H., Jang, H., Shin, D., Baek, S. H., & Roh, J.-L. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1284-8 · Cited by 77

Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression

Dong, L., Zhou, Q., Zhang, Z., Zhu, Y., Duan, T., & Feng, Y. (2012) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2011.01839.x · Cited by 77

Inflammation, DAMPs, Tumor Development, and Progression: A Vicious Circle Orchestrated by Redox Signaling

Castellani, P., Balza, E., & Rubartelli, A. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.5164 · Cited by 85

Targeting the duality of cancer

Arbiser, J. L., Bonner, M. Y., & Gilbert, L. C. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0026-x · Cited by 72

The Impact of miRNA-Based Molecular Diagnostics and Treatment of NRF2-Stabilized Tumors

Yamamoto, S., Inoue, J., Kawano, T., Kozaki, K., Omura, K., & Inazawa, J. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0246-t · Cited by 72

Regulation of Keap1-Nrf2 signaling in health and diseases

Xiao, J.-L., Liu, H.-Y., Sun, C., & Tang, C. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09771-4 · Cited by 70

Alkylating Agent–Induced NRF2 Blocks Endoplasmic Reticulum Stress–Mediated Apoptosis via Control of Glutathione Pools and Protein Thiol Homeostasis

Zanotto‐Filho, A., Masamsetti, V. P., Loranc, E., Tonapi, S. S., Gorthi, A., Bernard, X., Gonçalves, R. M., Moreira, J. C. F., Chen, Y., & Bishop, A. J. R. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0271 · Cited by 68

p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2

Cloer, E. W., Siesser, P. F., Cousins, E. M., Goldfarb, D., Mowrey, D. D., Harrison, J. S., Weir, S., Dokholyan, N. V., & Major, M. B. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00644-17 · Cited by 69

miR-432 Induces NRF2 Stabilization by Directly Targeting KEAP1

Akdemir, B., Nakajima, Y., Inazawa, J., & Inoue, J. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0232 · Cited by 62

New developments in mechanisms of prostate cancer progression

Howard, N., Clementino, M., Kim, D., Wang, L., Verma, A., Shi, X., Zhang, Z., & DiPaola, R. S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.003 · Cited by 62

NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma

Cescon, D. W., She, D., Sakashita, S., Zhu, C., Pintilie, M., Shepherd, F. A., & Tsao, M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2206 · Cited by 60

NRF2 transcriptionally activates the heat shock factor 1 promoter under oxidative stress and affects survival and migration potential of MCF7 cells

Paul, S., Ghosh, S., Mandal, S., Sau, S., & Pal, M. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003376 · Cited by 61

Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway

Liao, H., Zhu, D., Bai, M., Chen, H., Yan, S., Yu, J. Q., Zhu, H., Zheng, W., & Fan, G. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01470-x · Cited by 47

Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2

Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839

Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer

Ma, X., Zhang, J., Liu, S., Huang, Y., Chen, B., & Wang, D. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1722-9 · Cited by 88

Targeting the NRF2/KEAP1 pathway in cervical and endometrial cancers

Tossetta, G., & Marzioni, D. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175503 · Cited by 81

T-Box Transcription Factor 2 Enhances Chemoresistance of Endometrial Cancer by Mediating NRF2 Expression

Zhuang, S., Ding, N., Zhang, T., & Yu, X. (2022) · Current Protein and Peptide Science · doi:10.2174/1389203723666220823152239 · Cited by 7